Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction

Core Insights - Can-Fite BioPharma Ltd. has received a patent from the Brazilian Patent Office for the use of A3 Adenosine Receptor Agonists in treating sexual dysfunction, enhancing its intellectual property portfolio in a significant pharmaceutical market [1][3] Group 1: Patent and Market Implications - The granted patent provides protection in Brazil for Can-Fite's proprietary A3AR agonists, which is crucial as Brazil is one of the largest pharmaceutical markets in Latin America with increasing demand for innovative sexual health therapies [1][2] - The patent validates the therapeutic versatility of A3 adenosine receptor agonists and may lead to future commercialization opportunities in Latin America [3] Group 2: Company Overview and Drug Development - Can-Fite is an advanced clinical stage drug development company targeting multi-billion-dollar markets in cancer, liver, and inflammatory diseases [4] - The company's lead drug candidate, Piclidenoson, has reported topline results in a Phase III trial for psoriasis and is advancing in other trials for hepatocellular carcinoma and pancreatic cancer [4] - Can-Fite's drug candidate Namodenoson has received Orphan Drug Designation in the U.S. and Europe and is being evaluated in multiple clinical trials [4]